Overview

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.

Phase:

Phase 4

Details

Lead Sponsor:

Tennessee Retina

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept
Endothelial Growth Factors